OOIR: Observatory of International Research

Papers

(The H4-Index of Annals of Clinical and Translational Neurology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”	467
Blood neurofilament light: a critical review of its application to neurologic disease	155
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France	95
Long COVID‐19: Objectifying most self‐reported neurological symptoms	88
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort	87
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study	69
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19	65
Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study	61
Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy	57
Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound	57
Comparison of Simoa^TM and Ella^TM to assess serum neurofilament‐light chain in multiple sclerosis	55
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy	52
230 days of ultra long‐term subcutaneous EEG: seizure cycle analysis and comparison to patient diary	50
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions	48
Evolution of neurologic symptoms in non‐hospitalized COVID‐19 “long haulers”	47
Experiences of telemedicine in neurological out‐patient clinics during the COVID‐19 pandemic	47
Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study	44
The brain–heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention	43
Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients	43
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy	42
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes	41
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface	40
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder	39
Acute disseminated encephalomyelitis in a patient vaccinated against SARS‐CoV‐2	39
Spinocerebellar ataxia clinical trials: opportunities and challenges	38

Obesity and the risk of Multiple Sclerosis. The role of Leptin	37
Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children	37
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment	37
Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome	36
Interictal spike networks predict surgical outcome in patients with drug‐resistant focal epilepsy	35
Synaptic density in carriers of C9orf72 mutations: a [¹¹C]UCB‐J PET study	35
Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy	35
Mendelian etiologies identified with whole exome sequencing in cerebral palsy	33